Bladder Cancer

Midwest CEPAC

Due to the COVID-19 pandemic, the bladder cancer assessment will be paused now, to resume in 2-3 months.


ICER plans to assess the comparative clinical effectiveness and value of nadofaragene firadenovec (Instiladrin®, FKD Therapies Oy and Ferring Pharmaceuticals) for the treatment of bladder cancer. Nadofaragene firadenovec has received a  fast track and breakthrough therapy designation from the FDA, with an anticipated decision expected in mid-2020.

Review date: November 2020

For more information, please contact Maggie O’Grady, Program Manager, at mogrady@icer-review.org.

Associated Meetings

November 20, 2020 9:30 am - 4pm CT

TBD


Key Dates

Associated Materials

02/20/2020 – 03/10/2020

03/13/2020

03/13/2020 – 06/01/2020
Public Comments

03/13/2020

06/12/2020
Revised Scoping Document

07/14/2020
Research Protocol

08/06/2020
Model Analysis Plan

09/17/2020
Draft Evidence Report

09/17/2020
Draft Voting Questions

09/17/2020 – 10/15/2020
Public Comments

11/06/2020
Revised Voting Questions

11/06/2020
Response to Public Comments

11/06/2020
Evidence Report

11/20/2020
Meeting Agenda

11/20/2020
Evidence Presentation

12/15/2020
Final Evidence Report and Meeting Summary

12/15/2020
Report-at-a-Glance

12/15/2020
Final Policy Recommendations